Natalie Cvijanovich, MD

12/2020 - Diversity, Equity and Inclusion Champion Training, University of California
MD, - , Duke University School of Medicine
- Pediatric Critical Care, Primary Children's Hospital Medical Center
- Pediatrics, University of Utah School of Medicine
Honors and Awards
  • Excellence in Teaching, UCSF School of Medicine, 2021
  • FLAG Award, UCSF School of Medicine, 2021
  • Major Research Achievement Award, Children's Hospital Oakland Medical Staff, 2017
  1. Integrated PERSEVERE and endothelial biomarker risk model predicts death and persistent MODS in pediatric septic shock: a secondary analysis of a prospective observational study.
  2. Health Impairments in Children and Adolescents After Hospitalization for Acute COVID-19 or MIS-C.
  3. Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
  4. Life-Threatening Complications of Influenza versus COVID-19 in U.S. Children.
  5. A Description of COVID-19-Directed Therapy in Children Admitted to US Intensive Care Units 2020.
  6. Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C.
  7. BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
  8. Frequency, Characteristics and Complications of COVID-19 in Hospitalized Infants.
  9. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022.
  10. Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12-18 Years - United States, July-December 2021.
  11. Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.
  12. Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12-18 Years - United States, June-September 2021.
  13. Data-driven clustering identifies features distinguishing multisystem inflammatory syndrome from acute COVID-19 in children and adolescents.
  14. Multisystem Inflammatory Syndrome in Children - Initial Therapy and Outcomes.
  15. Neurologic Involvement in Children and Adolescents Hospitalized in the United States for COVID-19 or Multisystem Inflammatory Syndrome.
  16. Recalibration of the Renal Angina Index for Pediatric Septic Shock.
  17. Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C) Compared With Severe Acute COVID-19.
  18. Proprotein Convertase Subtilisin/Kexin Type 9 Loss-of-Function Is Detrimental to the Juvenile Host With Septic Shock.
  19. PERSEVERE Biomarkers Predict Severe Acute Kidney Injury and Renal Recovery in Pediatric Septic Shock.
  20. Early Enteral Nutrition Is Associated With Improved Clinical Outcomes in Critically Ill Children: A Secondary Analysis of Nutrition Support in the Heart and Lung Failure-Pediatric Insulin Titration Trial.
  21. Severe acute kidney injury is independently associated with mortality in children with septic shock.
  22. A Single Institution’s Experience with Later Extracardiac Fontan Procedure Off Bypass.
  23. Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model.
  24. Evaluation of Mannose Binding Lectin Gene Variants in Pediatric Influenza Virus-Related Critical Illness.
  25. Short-Term Adverse Outcomes Associated With Hypoglycemia in Critically Ill Children.
  26. Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness.
  27. Hyperchloremia is associated with acute kidney injury in pediatric patients with septic shock.
  28. Changes in Pediatric-Sized Endotracheal Tube Cuff Pressure With Elevation Gain: Observations in Ex Vivo Simulations and In Vivo Air Medical Transport.
  29. Endotype Transitions During the Acute Phase of Pediatric Septic Shock Reflect Changing Risk and Treatment Response.
  30. Hyperchloremia Is Associated With Complicated Course and Mortality in Pediatric Patients With Septic Shock.
  31. 413.
  32. Improved Risk Stratification in Pediatric Septic Shock Using Both Protein and mRNA Biomarkers. PERSEVERE-XP.
  33. Evaluation of IFITM3 rs12252 Association With Severe Pediatric Influenza Infection.
  34. Glucocorticoid Receptor Polymorphisms and Outcomes in Pediatric Septic Shock.
  35. Pediatric Sepsis Biomarker Risk Model-II: Redefining the Pediatric Sepsis Biomarker Risk Model With Septic Shock Phenotype.
  36. Combining Prognostic and Predictive Enrichment Strategies to Identify Children With Septic Shock Responsive to Corticosteroids.
  37. Prospective Testing and Redesign of a Temporal Biomarker Based Risk Model for Patients With Septic Shock: Implications for Septic Shock Biology.
  38. Differential expression of the Nrf2-linked genes in pediatric septic shock.
  39. A Multibiomarker-Based Model for Estimating the Risk of Septic Acute Kidney Injury.
  40. Safety and Dose Escalation Study of Intravenous Zinc Supplementation in Pediatric Critical Illness.
  41. Developing a clinically feasible personalized medicine approach to pediatric septic shock.
  42. Differential expression of the nuclear-encoded mitochondrial transcriptome in pediatric septic shock.
  43. Corticosteroids and pediatric septic shock outcomes: a risk stratified analysis.
  44. ABSTRACT 232.
  45. ABSTRACT 314.
  46. ABSTRACT 737.
  47. Corticosteroids are associated with repression of adaptive immunity gene programs in pediatric septic shock.
  48. The temporal version of the pediatric sepsis biomarker risk model.
  49. Post-ICU admission fluid balance and pediatric septic shock outcomes: a risk-stratified analysis.
  50. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model.
  51. Biomarkers and genetics of brain injury risk in diabetic ketoacidosis: A pilot study.
  52. Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children.
  53. The pediatric sepsis biomarker risk model.
  54. Identification of candidate serum biomarkers for severe septic shock-associated kidney injury via microarray.
  55. Validation of a gene expression-based subclassification strategy for pediatric septic shock.
  56. The influence of developmental age on the early transcriptomic response of children with septic shock.
  57. Diagnosis influences response of cerebral near infrared spectroscopy to intracranial hypertension in children.
  58. Identification of pediatric septic shock subclasses based on genome-wide expression profiling.
  59. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum.
  60. Zinc homeostasis in pediatric critical illness.
  61. Zinc supplementation in critically ill patients: a key pharmaconutrient?
  62. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock.
  63. Validating the genomic signature of pediatric septic shock.
  64. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock.
  65. Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock.
  66. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome.
  67. Clinical trial design--effect of prone positioning on clinical outcomes in infants and children with acute respiratory distress syndrome.
  68. Prone Positioning in Children With Acute Lung Injury—Reply.
  69. Effect of prone positioning on clinical outcomes in children with acute lung injury: a randomized controlled trial.
  71. A population-based assessment of pediatric all-terrain vehicle injuries.
  72. A population-based study of crashes involving 16- and 17-year-old drivers: the potential benefit of graduated driver licensing restrictions.
  73. All Terrain Vehicle (ATV) Injuries among Utah Children: 1992-1996.